An Early Phase 1 interventional study of UTAA91 injection in Systemic Sclerosis (SSc), sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Scleroderma, Systemic with a site in China — 64 open to participants now, 69 under way, 4 of them phase 3. Scleroderma, Systemic · China.
Among the 82 studies in Scleroderma, Systemic with a site in China, this one is the 33rd largest by planned enrollment of the 77 interventional ones that give a count, is one of 29 that started in 2025, is one of 40 in phase 1, reaches primary completion later than 43 of the 68 other live ones, and was the 48th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →64 of the 82 studies in Scleroderma, Systemic with a site in China are open now. Recruiting first, the newest first:
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in China, United States, Argentina and 42 more countries
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 13 · Phase 3 7 · Phase 4 4
First in 2008; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 20 across the 77 interventional studies, 490 across the 5 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 82 have an industry lead sponsor. The 10 most frequent:
PersonGen BioTherapeutics (Suzhou) Co., Ltd. is the lead sponsor of 43 studies on the registry; 17 are open to participants now.
PersonGen BioTherapeutics (Suzhou) Co., Ltd. has 5 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
17 of the studies in Scleroderma, Systemic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06822881Beijing GoBroad HospitalCT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) | 2026-12-31 |
| NCT06548607Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases | 2026-12-31 |
| NCT07641634Prolium Bioscience, IncA Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | 2027-01 |
| NCT06775912Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | 2027-01-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 82 studies in Scleroderma, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: UTAA91 injection
CAR-modified gamma delta T cells
Adverse events
The types, frequency, and severity of adverse events (AEs) and laboratory abnormalities (according to the Common Terminology Criteria for Adverse Events, NCI CTCAE 5.0).
Time frame: About 1 year
Cmax
Maximum concentration of UTAA91 injection amplified in peripheral blood after administration of the drug
Time frame: About 1 year
Tmax
Time to reach maximum concentration in peripheral blood after administration of UTAA91 injection
Time frame: About 1 year
Disease remission rate
The disease remission/response/improvement rates at 28 days, 2 months, and 3 months after treatment with UTAA09 injection.
Time frame: About 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Dec 2027, 30 months later.
Of 44 phase 1 interventional studies under Scleroderma, Systemic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: UTAA91
PersonGen BioTherapeutics (Suzhou) Co., Ltd. →